Sign in
Taking people in AustriaPhase 2

Drug combination for sudden kidney failure caused by multiple myeloma

Tests a daratumumab-based combination in multiple myeloma causing kidney failure.

Key facts

Who runs it
Medizinische Universitaet Innsbruck
Where
Innsbruck, AustriaSee the site
Registry title
Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
29 Oct 2024
Expected to end
1 Sept 2032
Type of study
Interventional
Record updated
29 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed, untreated multiple myeloma whose kidneys have failed because of the myeloma, including people who need dialysis.

Age
18 to 70 years
Sex
Men and women can join.
Disease stage
Untreated multiple myeloma that needs treatment, with kidney failure caused by the myeloma: either needing dialysis, or an estimated creatinine clearance under 30 ml/min. The disease must be measurable on blood or urine tests.
Earlier treatment
No earlier myeloma treatment in the last 21 days, apart from limited steroid treatment. No other cancer in the last 2 years, except some skin, cervix or breast cancers that were fully removed.
Biomarker or test result
Measurable myeloma: serum M-protein of 10g/l or more, or urine M-protein of 200mg/24h or more, or involved serum light chain of 10mg/dl or more with an abnormal FLC ratio. Neutrophils above 1.000/mm3, platelets above 50.000/mm3, bilirubin up to 2 x ULN, ALT and AST up to 3 x ULN.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Active infection, active hepatitis B or C, or known HIV
  • Another cancer in the last 2 years, or any remaining sign of an earlier cancer
  • Severe kidney impairment that existed before the myeloma, with eGFR under 30 ml/min/1.73 m2
  • Heart problems that are not controlled, or a heart attack in the last 6 months

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Patients in need of therapy with untreated multiple myeloma and myeloma induced renal failure either requiring dialysis, or with renal insufficiency with an estimated creatinine clearance <30 ml/min
  • Disease free of prior malignancies for ≥ 2 years with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma “in situ” of the cervix or breast if they have undergone complete resection
  • Female patients who Are older than 50 years and postmenopausal for at least 1 year before the screening visit, OR
  • Female patients who Are surgically sterile, OR
  • Female patients who If they are of childbearing potential, agree to practice 2 effective methods of contraception at the same time, from 4 weeks before starting study therapy through 90 days after the last dose of study drug, OR
  • Female patients who Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
  • Female patients who Are informed and understand the possible consequences of the teratogenic potential of pomalidomide
  • Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug
  • Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject
  • Male patients are informed and understand the possible consequences of the teratogenic potential of pomalidomide
  • Male or female patients 18 years to 70 years
  • Voluntary written consent must be given before start of antimyeloma treatment, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
  • Patients must have measurable disease defined by at least 1 of the following criteria: Serum M-protein ≥ 10g/l Urine M-protein ≥ 200mg/24h sFLC assay: involved serum light chain ≥ 10mg/dl provided that FLC ratio is abnormal
  • Life expectancy > 3 months
  • ECOG ≤ 3 (ECOG 3 solely defined by being bedridden or in need of care due to dialysis catheter and/or elevated retention parameters and/or other myeloma induced impairment, e.g. osteolytic bone pain). Pat. must have had ECOG ≤ 2 before myeloma diagnosis
  • Absolute neutrophil count (ANC) > 1.000/mm3 and platelet count > 50.000/mm3. Platelet transfusions to help patients meet eligibility criteria are allowed within 3 days before study enrollment
  • Total bilirubin ≤ 2 x ULN
  • ALT and AST ≤ 3 x ULN

Who cannot take part

  • Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with basal cell, squamous cell carcinoma of the skin, or carcinoma “in situ” of the cervix or breast with are not excluded if they have undergone complete resection
  • Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
  • Previous anti-myeloma treatment within the last 21 days prior to baseline visit (cycle 1 / day 1), except corticosteroid therapy (<=160 mg dexamethasone or corticosteroid dose equivalent for a maximum of 5 days prior to d1c1)
  • Major surgery within 14 days before enrollment
  • Radiotherapy within 14 days before enrollment, except local radiation for pain and/or instable bones
  • Systemic treatment, within 14 days before the first dose of study medication, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A4 (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A4 inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort (interference with the metabolization of pomalidomide)
  • Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of difficulty swallowing
  • Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
  • Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
  • Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol
  • Female patients who are lactating or have a positive serum pregnancy test during the screening period
  • Pre-existing documented severe renal impairment (before suspected MM diagnosis) with an eGFR of <30 ml/min/1.73 m2
  • Patient has ≥ grade 3 peripheral neuropathy
  • Clinical evidence of central nervous system involvement

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which of these best describes your myeloma treatment so far?
  • Has a doctor told you that your myeloma can be measured in your blood or urine tests?

Where in Austria

  • Medizinische Universitaet InnsbruckInnsbruck, AustriaTaking people

About the trial

What the trial wants to find out

To determine the safety and toxicity and the rate of renal recovery in newly diagnosed patients with multiple myeloma induced renal failure receiving daratumumab in combination with carfilzomib, pomalidomide and dexamethasone for 4 cycles.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
Plain-language title
Drug combination for sudden kidney failure caused by multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-514702-31-00, who can take part
Record updated
29 October 2024